This article is part of the latest Trends and Opportunities report, which outlines key themes for the next stage of this market cycle and their nuanced implications across global asset classes.

Healthcare and biotech sub-sector have outperformed the broader market through the drawdown and recovery phases of the past five sell-offs.

2022 Recap

• In a year marked by supply-chain disruptions, persistent inflation, and historically sharp rate hikes, equity sector dispersion across global equity markets was staggering. But healthcare broadly – and the biotech sector specifically – were somewhat insulated from the pain.
• Biotech began to recover in the second half of 2022 following the worst drawdown in the sector’s recent history (-64% vs. average biotech drawdown of -32%).¹
• Innovation in healthcare accelerated during the COVID-19 pandemic and continues to drive the sector forward. Novel drug approvals by the U.S. Food and Drug Administration (FDA) are at decades-high annual averages since 2018.²

Global equity sector returns for 2022

Outlook

• Given the uncertainty surrounding the severity of the impending economic slowdown, volatility is expected to persist in 2023.
• For the past two decades, the healthcare sector has proved resilient during market downturns, exhibiting lower average volatility and downside than global equities.
• At the same time, the sector continues to trade at a discount to longer-term averages, with many biotech companies in particular trading below levels of cash on their balance sheets, providing the potential for growth regardless of the recession outlook.
• In biotech, the ability to understand the science behind pending drug approvals, as well as the business impact of those approvals in the market, is critical to finding winners that can take advantage of the speed of innovation happening in the sector.

Healthcare and biotech have been resilient in market downturns and recoveries

PCS Perspective

• Taking a balanced approach to assessing both the defensive and growth characteristics of the healthcare index can help investors navigate the volatility ahead.
• Healthcare and the narrower biotech sub-sector have outperformed the broader market through the drawdown and recovery phases of the past five sell-offs.
• Paying close attention to near-term cash flows, valuations, and revenue generation is increasingly important in an environment where inflation may persist, and rates remain higher than in the previous decade.
• An active and nimble approach incorporating sector and portfolio construction expertise can help investors take advantage of the many long-term tailwinds healthcare can provide.

Footnotes

¹ Biotech performance is for SPDR^® S&P^® Biotech ETF (XBI). 64% drawdown occurred from 8 February 2021 through 11 May 2022 vs. average biotech drawdowns going back to 31 January 2006.

IMPORTANT INFORMATION

Actively managed portfolios may fail to produce the intended results. No investment strategy can ensure a profit or eliminate the risk of loss.

Health care industries are subject to government regulation and reimbursement rates, as well as government approval of products and services, which could have a significant effect on price and availability, and can be significantly affected by rapid obsolescence and patent expirations.